Oncopeptides investor relations material

Listen to the latest call from Oncopeptides

Oncopeptides AB, a biotech company, focuses on the development of therapies for patients with cancer. The company's lead drug candidate is melflufen, which has received orphan drug designation from the European Commission, as well as from the FDA for the treatment of multiple myeloma. Its product pipeline also comprises peptide-drug conjugates that are in preclinical stage development for hematological malignancies and solid tumors. The company is based in Stockholm, Sweden

Dig deeper into the Oncopeptides fundamentals on Quartr.